Navigation Links
Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinson's Congress
Date:10/2/2013

roups: placebo, 260 mg ADS-5102, 340 mg ADS-5102 and 420 mg ADS-5102.  Both the 340 mg and 420 mg ADS-5102 dose levels significantly reduced LID as measured by the change in Unified Dyskinesia Rating Scale (UDysRS) total score over eight weeks versus placebo, meeting the primary endpoint for the clinical study.  Of note, the reduction in LID was seen at two weeks following the first dose of study medication.  At week 8, the ON time without troublesome dyskinesia as measured by patient diaries was 11.0 hours, 11.5 hours, and 12.1 hours for the 260 mg, 340 mg, and 420 mg dose levels, respectively, compared to 8.0 hours for placebo.  These findings were statistically significant, demonstrating an increase of about 3 hours over placebo compared to baseline values.  ADS-5102 also demonstrated statistically significant functional improvement in dyskinesia as assessed by the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV, a measure of the degree of impact that dyskinesia has on the patient's daily function in terms of activities and social interactions.

Treatment with ADS-5102 did not result in worsening of PD, as measured by the MDS-UPDRS combined score (Parts I, II and III).  The adverse events reported in this study were typically mild to moderate in severity and consistent with Parkinson's disease and the known amantadine safety profile.  There was no difference from placebo in the incidence of sleep-related adverse events.

Data from the Phase 2/3 study were presented today in a poster entitled "Safety and Efficacy of ADS-5102 in Levodopa-Induced Dyskinesia (EASED Study)" (Abstract #1311.00) at 11:30 am ET at the World Parkinson's Congress in Montreal, Canada.  The poster has also been selected for a "Guided Poster Tour" between 5:15-6:45 pm ET.  Additional details of the EASED study results may be found on the Adamas website.

About the EASED
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
2. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
3. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
4. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LA JOLLA, Calif. , Sept. 18, 2014 ... RGLS ), a biopharmaceutical company leading the ... announced today it has initiated its ATHENA natural ... syndrome, a life-threatening genetic kidney disease with no ... characterize the natural decline of renal function markers ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that the Company,s President and ... , will present at the 7 th ... September 24, 2014 at 11:20 a.m. EDT.  ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
(Date:9/18/2014)... 2014 Kent, WA Chiropractor Danene Saggau ... pleased to announce that Dawn Kelly has agreed to become ... Saggau looks forward to Ms. Kelly expanding her role within ... make her a key contributor. “ Dawn Kelly brings ... and personal experiences that will allow me to focus ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Memorial ... made history this week by performing the first ever, ... UNOS (United Network for Organ Sharing) approval to launch ... one of only two programs in South Florida. ... Dr. Enrique Gongora, Medical Director of the ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Exposure to diverse communities may ... Hearing different languages in the park or ... learn from people who are different from them, researchers ... adults, are often biased against interacting with and learning ... Woodward, a University of Chicago psychology professor, said in ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay News) -- ... starting to spread faster than ever, the World Health Organization said ... infection were reported in just one week. That brings the ... of those reported in the past three weeks, the Associated ... WHO has estimated that as many as 20,000 people could eventually ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 It’s been just ... their newest, patent pending bunion splint to website visitors, but ... Rosa, wrote: "I was absolutely delighted. It is perfect and ... I am wearing them. THANK YOU FOR LISTENING!!!" Another ... by saying, "The hole used to slip to the end ...
Breaking Medicine News(10 mins):Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3
... - New $2.1 Million SBIR Grant Extends NHGRI ... Whole Genome Imaging and Analysis Platform -PHILADELPHIA, March ... nanoscale platforms for biomedical research, molecular diagnostics and ... II grant from the National Human Genome Research ...
... During the 14th International Salon of,Ophthalmologic Optics held ... the Second National Optical Award Grand Prix MSOO. , ... of optical products got their first,opportunity to choose the ... together with Expocentre, the largest exhibition,organization of Russia, announced ...
... Way People Think About End-of-LifeReceives Praise from Award-Winning Documentary Filmmaker ... the nation,s leading non-profit hospice organizations, has produced a documentary ... will be televised on Detroit Public Television on Monday, March ... 29 from 4:30 - 5:30 pm. For television ...
... relationship agreement that Legacy Hospital Partners, Inc. (LHP), based in Plano, ... range of supply chain and procurement services to help manage spending ... ... March 17, 2009-- Broadlane announced today through a corporate relationship agreement ...
... study by the Stanley Medical Research Institute and Johns ... to neurotic behavior in infected men and women. Between ... and 30 percent of the U.S. population - may be ... then passed to humans when changing cat litter, gardening and ...
... one of the few area surgeons performing the Reverse Shoulder Replacement ... ... -- A breakthrough shoulder surgery is restoring function and relieving pain ... a damaged rotator cuff, a failed shoulder replacement surgery or severe ...
Cached Medicine News:Health News:BioNanomatrix Awarded Phase II NIH Grant to Support Development of Its Single-Molecule Nanoscale Whole Genome Analyzer 2Health News:Prizes of the Grand Prix MSOO Award Presented in Moscow 2Health News:Hospice of Michigan Documentary to Air on Detroit Public Television Monday, March 23 and Sunday, March 29 2Health News:New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services 2Health News:New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services 3Health News:New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services 4Health News:Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 3Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 4
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
Calibration plasmas for Assays of Low Molecular Weight Heparins (LMWH)using the Anti-Xa method on STA© Analyzers....
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
Medicine Products: